Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose ProtectionAccesswire • 12/19/22
Ensysce Biosciences Announces Completion of Clinical Portion of Overdose Protection Trial PF614-MPAR-101-Part AAccesswire • 12/05/22
Ensysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for PF614Accesswire • 11/14/22
Ensysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, a TAAP Abuse-Deterrent Oxycodone Extended-Release ProductAccesswire • 10/31/22
Ensysce Biosciences Announces First Subjects Dosed in Second Human Abuse Potential StudyAccesswire • 10/28/22
Ensysce Biosciences, Inc. Announces Participation in LD Micro Main Event XV ConferenceNewsfile Corp • 10/12/22
Ensysce Biosciences Announces Initiation of Second Human Abuse Potential Study, Being Conducted by DVCRAccesswire • 09/22/22
Ensysce Biosciences to Present at Benzinga All Access Event on Friday, September 23, 2022Accesswire • 09/21/22
Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and OverdosePRNewsWire • 08/31/22
Ensysce Biosciences Debuts Redesigned Company Website to Highlight its TAAP(TM) and MPAR(TM) Technologies and Growing Product PipelineAccesswire • 08/31/22
Ensysce Biosciences Announces Completion of Clinical Portion of Human Abuse Potential Trial PF614-103Accesswire • 08/23/22
Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update CallAccesswire • 08/17/22
Ensysce Biosciences Provides Business Update and Reports Second Quarter 2022 Financial ResultsAccesswire • 08/11/22
Ensysce Biosciences Announces Completion of $8 Million Convertible Note FinancingAccesswire • 08/09/22
Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update CallAccesswire • 07/27/22